Monitoring of whole blood viscosity (WBV) is critical in patients at risk of hyperviscosity (The
Royal College of Pathologies of Australia, 2019). Prothrombin Time Test (PT/INR), which is currently used is insufficient to predict bleeding risk (Cao et al., 2024). There is a test for blood viscosity, which is cheaper than currently recommended plethora of tests, but clinicians are unaware that haematocrit and serum protein, can be used in an algorithm to obtain eWBV that is specific for the cardiovascular phenomenon (Nwose & Bwititi, 2022).